NBC’s Today Show featured a return of the Berns Triplets and their physician, Dr. Jill Waibel on Friday Nov. 6th 2009, The segment followed up with Chandra, Jordan and Trae Berns after their first appearance on the Today Show on May 28th 2009 in which they were interviewed by Matt Lauer regarding their treatments by Dr. Jill Waibel of Miami, FL with Lumenis’ UltraPulse TotalFX laser.
(PRWEB) November 9, 2009 -- NBC’s Today Show featured a return of the Berns Triplets and their physician, Dr. Jill Waibel on Friday Nov. 6th 2009, The segment followed up with Chandra, Jordan and Trae Berns after their first appearance on the Today Show on May 28th 2009 in which they were interviewed by Matt Lauer regarding their treatments by Dr. Jill Waibel of Miami, FL with Lumenis’ UltraPulse TotalFX laser.
The return segment, which aired Friday, November 6th, clearly showed viewers the dramatic improvement in the burn scars of all three sisters – scars which were inflicted upon them in an arson fire as infants. After twenty years of seeking treatment, they have found hope with Dr. Jill Waibel and Lumenis’ UltraPulse TotalFX system. Their remarkable results have inspired many other people with burn scars around the world to seek out Dr. Waibel and the TotalFX treatment to help them with their own scars.
“Chandra, Jordan and Trae have all shown considerable improvement in their scars after treatments using Lumenis’ TotalFX”, commented Dr. Waibel. “Because of their amazing progress, word has spread and I’ve treated over a hundred other burn patients in my practice alone. We are quickly advancing our knowledge on the science behind burn scars and the best solution for treatment”. Dr. Waibel is now a frequent guest lecturer on burn scar treatments at many physician societies and has quickly established herself as the physician’s resource for scar revision.
“It’s important that we continue to learn and explore the best possible solutions for these types of treatments” cautioned Dr. Waibel. “Not all lasers are alike, and although other lasers may be indicated for scar revision, my treatment of choice is the TotalFX.” The TotalFX treatment is powered by Lumenis’ UltraPulse CO2 laser and the UltraPulse is the only laser available that delivers energy in the patented UltraPulse mode.
Lumenis pioneered skin resurfacing over 18 years ago with its C02 lasers. The Lumenis UltraPulse laser system has FDA clearance for more than 34 indications and is referenced in excess of 90 peer-reviewed publications. Although frequently used for aesthetic applications, the UltraPulse offers 240 watts of power and microsecond pulses which combined provide a broad canvas from which other treatments in cutaneous surgical and aesthetic applications can be provided. No other laser available today offers UltraPulse delivery and remains the standard for treating scars among all CO2 lasers.
The entire story of the Berns triplets and their treatments using the UltraPulse Fractional CO2 laser can be found at www.bernstriplets.com. For more information on the UltraPulse laser go to www.aesthetic.lumenis.com
About Lumenis
Lumenis is Israel’s largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, presence in over 100 countries worldwide, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto www.lumenis.com.
Lumenis® is a registered trademark of Lumenis Ltd.
UltraPulse® is a trademark of Lumenis Ltd.
For further information contact:
Michelle Maydan
Director of Corporate Communications
1-866-569-0597
+972-4-959-9004
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical tr, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.
###
